A phase II trial was conducted to determine which of the three possible two-drug combinations of diaziquone, etoposide and mitoxantrone was associated with the highest response rate in patients with relapsed or refractory acute myeloid leukemia (AML). Of the 167 patients (median age 55) with AML who entered the trial, 123 were in first relapse, 22 were in second relapse and 22 had failed to achieve complete remission (CR). CR rates were 30% for diaziquone and mitoxantrone, and 23% for the other two combinations (mitoxantrone/etoposide and diaziquone/etoposide), NS. Patients in first relapse had higher CR rates (40%) than other patients. Of the 166 patients who actually received treatment, 43 died before having either a CR or persistent leukemia. Non-hematologic toxicity was primarily mucosal with 24% of patients experiencing grade 3 or greater stomatitis on the two diaziquone arms, and 43% on the mitoxantrone/etoposide arm. The combination of diaziquone and mitoxantrone was selected for further testing in patients with AML.
Introduction
Despite considerable advances in the knowledge about events at the molecular level associated with the development of the acute leukemias and other cancers, the majority of patients diagnosed with acute myeloid leukemia (AML) still die of their disease. Treatment approaches remain empiric, and the major improvements in outcome for patients with AML can be ascribed to the development of induction chemotherapy with the combination of an anthracycline and cytosine arabinoside (Ara-c), and the administration of intensive post-remission chemotherapy. With administration of high doses of currently available chemotherapy drugs, the best published results document survival of less than half of all patients treated. 1 Other strategies have been tried in an attempt to improve upon these results. One approach has utilized hematopoietic colony-stimulating factors either to reduce the morbidity and mortality of treatment or to induce a greater susceptibility to chemotherapy. A large number of studies have recently been reported with mixed results, [2] [3] [4] [5] [6] [7] [8] and this strategy does not seem likely to have a major impact. Currently, a number of studies are utilizing modulators of multi-drug resistance proteins to enhance intracellular accumulation of anti-leukemia drugs such as anthracyclines or etoposide in the hopes of affecting resistant sub-populations of leukemic cells. As yet, no clinical evidence of improved response is available from these trials.
The use of alternative drugs with activity in AML has been 10 demonstrated that the alkylating agent diaziquone (AZQ), when given as a single agent, is associated with a complete remission (CR) rate of approximately 25% in patients with relapsed AML and that some of these patients may have prolonged disease-free survival after treatment with a single cycle of AZQ. Two of the six patients who achieved CR in the initial UMCC trial continue in CR at 13 and 14 years after a single cycle of treatment.
The CALGB initiated a series of studies to identify combinations of these agents for eventual use in newly diagnosed patients. AZQ was selected along with etoposide and mitoxantrone for further testing. Initially, a series of phase I trials was performed in patients with relapsed or refractory leukemia. At the University of Maryland Cancer Center, a combination of AZQ and etoposide was tested.
11 Concurrently, phase I trials conducted within CALGB explored the combinations of etoposide and mitoxantrone, 12 and mitoxantrone and AZQ. 13 Complete remissions occurred in all three studies in patients with AML and all three trials identified the same maximum tolerated doses of each drug. The maximum tolerated doses were mitoxantrone 12 mg/m 2 /day given as an i.v. bolus for each of 3 consecutive days, etoposide delivered as a continuous infusion at a dose of 150 mg/m 2 /day for 5 days, and AZQ given at a dose of 28 mg/m 2 /day by continuous i.v. infusion for 5 consecutive days. The infusional schedule for AZQ was based on trials documenting the schedule dependency of this drug. 9 Etoposide was also given as a continuous infusion based on pharmacologic data suggesting a potential advantage for this schedule, and the report of a high CR rate in a leukemia trial using this schedule. 14 In order to choose a two-drug regimen for further study, a randomized phase II trial (CALGB 8722) was organized in which patients with relapsed or refractory AML would receive two of the three agents. Thus each patient was randomized to receive one of the three possible two-drug combinations: AZQ/etoposide; AZQ/mitoxantrone; or mitoxantrone/ etoposide. The intent was that the combination with the highest CR rate would be selected to be utilized as post-remission therapy for patients with newly diagnosed AML and would be compared to Ara-c as a single agent as post-remission therapy.
Patients, materials and methods

Eligibility criteria
Patients were eligible for this trial if they had a diagnosis of AML as defined morphologically by the French-AmericanBritish classification system. Patients who had relapsed after chemotherapy or were refractory (did not achieve CR following initial induction therapy) were eligible. Patients were required to have a bone marrow aspirate demonstrating 30% or greater replacement of non-ethyroid elements by myeloblasts. Patients with a prior history of myelodysplasia, other hematologic malignancies or exposure to chemotherapy for other malignancies were not excluded. Additionally, patients were required to have normal hepatic and renal function with bilirubin and creatinine values less than twice the upper limit of normal, and could not have received more than the equivalent of 450 mg/m 2 of daunorubicin prior to study entry.
Registration and randomization procedures
Patients were registered and simultaneously randomized to one of the three treatment groups by a telephone call to the CALGB Central Office. The treatment assignment was provided via a randomized permuted block design 15 prepared by the CALGB Statistical Center. Response to prior treatment (relapsed or refractory) was the only stratification factor.
Quality control, quality assurance and auditing All data forms were sent to the CALGB Statistical Center where they were reviewed prior to data entry by the data coordinator assigned to the study. Data were entered into the official CALGB database by the data entry staff. The study chair reviewed the eligibility of each patient as well as all data forms in order to verify the institutional assessments of toxicity and response. Members of the CALGB Data Audit Committee visit all the participating institutions at least once every 3 years to verify compliance with federal regulations and protocol requirements, including those pertaining to eligibility, treatment, response and follow-up. 16 
Treatment design
As noted above, patients were randomized to receive one of three combinations including AZQ (28 mg/m 2 /day for 5 days by continuous i.v. infusion), etoposide (150 mg/m 2 /day by continuous i.v. infusion for 5 consecutive days) and mitoxantrone (12 mg/m 2 /day each day for 3 consecutive days). A second course of chemotherapy was permitted at day 14 or after if a bone marrow showed significant residual leukemia. Thereafter, patients either achieved complete remission or were considered off study. No post-remission treatment was prescribed by the protocol. Patients were permitted to be entered into post-remission treatment programs at their physicians' direction.
Outcome measures
Complete remission (CR) was defined according to the criteria established by the NCI Workshop. 17 It was required that these findings persist for at least 4 weeks in the absence of further treatment.
Relapse of AML was defined as marrow infiltration by greater than 25% leukemic cells in a previously remission bone marrow. The length of disease-free survival was the interval from the day of remission to the day of relapse (bone marrow or non-marrow), date of death for any cause or date last known to be in remission. Overall survival was measured from the time of registration to death from any cause.
The duration of neutropenia (in days) was defined as the number of days required for the absolute neutrophil count to increase to greater than 500/l from the day of initiation of chemotherapy. The duration of thrombocytopenia was defined as the number of days from the onset of chemotherapy to platelet transfusion independence with maintenance of a platelet count above 20 000/l.
Experimental design and statistical methods
This study was conducted as a randomized phase II clinical trial. 18 The purpose was not to compare the three treatments as in a standard phase III clinical trial, and the analysis did not require the selected treatment to be 'significantly' better than the other treatments by the usual testing procedures. Rather, the design required sufficient numbers of patients to be entered on each treatment to ensure a probability of at least 0.90 that the treatment with the highest response rate is the better treatment and conversely is not the inferior therapy. Assuming that two of the treatments would have a true complete response rate of 30% and that the third would have a true response rate of 45% yielded the requirement of 52 patients per treatment (156 total).
Comparisons of the response rates within patient characteristics were carried out by exact tests of 2 × K tables 19 and for those characteristics with ordered categories (age, leukocyte count, etc) by testing for a linear trend. 20 Survival time, duration of remission, and time to recovery of absolute neutrophil count to greater than 500/l distributions were estimated using the Kaplan-Meier method 21 and differences between treatment groups were tested using the log rank statistic. 22 Ninety-five percent confidence intervals on response rates and differences in response rates were calculated using standard statistical procedures. 23 Confidence intervals on medians for the duration of neutropenia, survival time from study entry, and length of remission were calculated by the BrookmeyerCrowley method. 24 All statistical analyses were carried out using either SAS software system or standard software developed by the CALGB Statistical Center and used on CALGB studies. In all cases, an 'intent to treat' analysis was carried out with all randomized patients included in their assigned treatment group.
Results
This study (CALGB 8722) was opened to patient accrual in November 1987, and closed in February 1990 after 167 patients (median age 55 years, range 19-77) were registered from 26 different CALGB main member institutions and their affiliates. Two patients were subsequently found to be ineligible. One patient was found to have acute lymphocytic leukemia (ALL) and never started treatment. This patient is not included in any subsequent analysis as no data were ever submitted to the Data Management Center. One patient was dis- covered to have previously received 584 mg/m 2 of anthracyclines exceeding the allowed limit of 450 mg/m 2 , and a third, eligible patient, was registered but did not receive any treatment. These last two patients are included in all analyses. Thus, analyses of treatment response and toxicity are based on 166 patients.
Selected patient characteristics are given in Table 1 . Response is presented in Table 2 . Overall, 42 of 166 patients (25%) achieved CR with the highest CR rate (30%) observed in the mitoxantrone/AZQ treatment group. For the other two treatment groups, mitoxantrone/etoposide and AZQ/etoposide, the CR rate was 23% each. Thus, by the statistical selection procedures established for this protocol, the mitoxantrone/AZQ treatment was selected for further evaluation. However, there was not a striking difference in CR rates among the three treatment regimens as indicated by the 95% confidence intervals: mitoxantrone/AZQ (18%, 43%); mitoxantrone/etoposide (12%, 36%); AZQ/etoposide (13%, 36%).
Patients in first relapse represented approximately 80% of the patients in each arm and CR rates in this subgroup were 40% for AZQ/mitoxantrone (16/40), 24% for mitoxantrone/etoposide (10/42) and 25% for AZQ/etoposide (10/40). The difference in CR rates between first relapse patients and others was significant (P = 0.03, Fisher exact test and P = 0.01, trend test). Survival time by treatment for all 167 patients is given in Figure 1 , and the duration of CR by treatment for the 42 patients with a CR is shown in Figure 2 .
Grade 3-5 toxicities occurring in more than 5% of patients are summarized in Table 3 . Mucosal toxicity occurred in each arm to a variable extent, with at least a 23-41% likelihood of grade 3 or greater toxicity, but was rarely grade 4. Grades 3 and 4 infection were also common, reflecting significant myelosuppression. Of the 166 patients who received chemotherapy on this study, 43 died before achieving a response or having persistent leukemia documented. These patients died at a median of day 33 (range 12-76 days). Of these 43 patients, 19 had been treated with AZQ/mitoxantrone, nine with mitoxantrone/etoposide, and 15 with AZQ/etoposide.
Hematologic toxicity was predictably grade 4 for leukopenia and thrombocytopenia. In patients who achieved a complete remission, the median time to an absolute neutrophil count (ANC) of Ͼ500/l was 34 days (range 27-60) for AZQ/mitoxantrone, 35 days (range 19-54) for mitoxantrone/etoposide and 31 days (range 33-64) for AZQ/etoposide. Similarly, the median time from initiation of chemotherapy to an untransfused platelet count Ͼ20 000/l was 36 days (range 25-70) for AZQ/mitoxantrone, 27.5 days (range 15-57) for mitoxantrone/etoposide, and 28 days (range 22-64) for AZQ/etoposide.
Figure 2
Kaplan-Meier plot of the duration of complete remission by arm for patients entered onto CALGB 8722. 
Discussion
The complete remission rates for the three arms in this randomized phase II study were not significantly different. Of the 57 patients treated with AZQ/mitoxantrone, 17 achieved CR (30%), while 23% of patients receiving either mitoxantrone/etoposide and AZQ/etoposide entered CR. The CR rates were higher for patients in first relapse (36/122, 30%) compared to second and subsequent relapse (6/45, 13%). For the patients in first relapse, the CR rate for AZQ/mitoxantrone was 40%, and the CR rate for the other two regimens was 24-25%. Several patients have achieved long-term disease-free survival. Of the 167 patients entered on this study, six are alive, three of whom underwent transplantation. These data further confirm the activity of AZQ, studied in a series of phase I and II studies at the University of Maryland Cancer Center and within CALGB. Conversely, the combination of mitoxantrone/etoposide did not fare as well as in some recent publications which reported CR rates in the range of 40% or greater. 14, 25 In contrast to these studies which included previously untreated patients as well as relapsed patients, all of the patients treated on this program were previously treated, and a higher dose of etoposide was used, administered as a continuous infusion. Other studies have given doses of mitoxantrone that exceed the 36 mg/m 2 given in this study. Nonetheless, that dose of mitoxantrone in combination with AZQ proved reasonably effective.
The toxicity of these combinations was primarily mucosal with stomatitis, mucositis, and diarrhea. Prolonged myelosuppression with approximately 5 weeks between initiation of treatment and recovery to у500 neutrophils/l and у20 000 platelets/l was also seen. These two toxicities in conjunction with the older age of the patients studied (median 55 years) explain the significant mortality rate associated with treatment.
After further feasibility studies in newly diagnosed patients, 26 ,27 the combination of AZQ/mitoxantrone was selected for further study as part of a randomized phase III comparison between two different post-remission treatment strategies: sequential cycles of high-dose Ara-c vs sequential cycles of intensive chemotherapy using different chemotherapy regimens (high-dose Ara-c followed by high-dose cytoxan/etoposide followed by AZQ/mitoxantrone/G-CSF). This phase III study is the culmination of a series of clinical trials that represent a logical strategy for new drug development in the treatment of patients with AML.
